New Second-Line Combo Therapy for MSS Metastatic Colorectal Cancer

This is a single-center, single-arm study designed to evaluate the efficacy and safety of second-line treatment in patients with advanced colorectal cancer (those who have progressed on or are intolerant to first-line oxaliplatin-based regimens with or without targeted therapy) receiving Levofolinic Acid + 5-FU continuous infusion combined with irinotecan hydrochloride liposome ± cetuximab/bevacizumab. Approximately 30 patients will be enrolled.

NCT Number	NCT07559760
Lead Sponsor	The First Hospital of Jilin University
Conditions	Metastatic Colorectal Cancer
Enrollment	30 participants
Start Date	2025-11-01
Primary Completion	2027-05-31 (estimated)
Study Completion	2029-05-31 (estimated)
Updated on ClinicalTrials.gov	2026-04-30